-
Mashup Score: 2
A major underlying cause of the resistance of solid tumor cells to cancer therapy is the evasion of cell death following anti-cancer drug treatment. We explored the combination of TRAIL-inducing compound ONC201/TIC10 and Bcl-xL/Bcl-2 inhibitor ABT-263 to target the extrinsic and intrinsic apoptotic …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Inhibition of GSK-3 using small-molecule elraglusib has shown promising preclinical antitumor activity. Using in vitro systems, we found that elraglusib promotes immune cell-mediated tumor cell killing, enhances tumor cell pyroptosis, decreases tumor cell NF-kappaB-regulated survival protein expression, and increases immune cell effector molecule secretion. Using in vivo systems, we observed…
Source: bioRxivCategories: Hem/Oncs, Latest HeadlinesTweet-
Sharing @bioRxivPreprint #eldeirylab Kelsey Huntington @BrownUPathoGP et al. @bcarneiro7 GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer https://t.co/A4JFSFDLNJ https://t.co/mgJlZgZjRR
-
-
Mashup Score: 0
Inhibition of GSK-3 using small-molecule elraglusib has shown promising preclinical antitumor activity. Using in vitro systems, we found that elraglusib promotes immune cell-mediated tumor cell killing, enhances tumor cell pyroptosis, decreases tumor cell NF-kappaB-regulated survival protein expression, and increases immune cell effector molecule secretion. Using in vivo systems, we observed…
Source: bioRxivCategories: Hem/Oncs, Latest HeadlinesTweet-
Sharing preprint from #eldeirylab by Kelsey Huntington @BrownUPathoGP et al. @bcarneiro7 GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer https://t.co/A4JFSFDLNJ
-
-
Mashup Score: 3
Hung and colleagues show that ALK-mediated CDK9 activation increases homologous recombination repair and PARP inhibition resistance and propose combinatorial inhibition of ALK and PARP as therapeutically beneficial for treatment-resistant tumors.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Dr. Ghandali presenting #eldeirylab @BrownUCancer elegant mechanistic, translational paper @NatureCancer showing preclinical efficacy of ALK + PARP inhibitors in breast & ovarian cancer from our colleagues Drs. Dihua Yu @MDAndersonNews Mien-Chie Hung https://t.co/qqo7BNz6qa https://t.co/1P9HmFxxNj
-
-
Mashup Score: 1Why I teach my students about scientific failure - 1 year(s) ago
“It’s a lesson I wish I’d learned before starting grad school,” this professor writes
Source: www.science.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Learning through initial lab competencies to make discoveries is part of our culture #eldeirylab @BrownUCancer Our students are making novel discoveries and publishing @BrownMedicine @AACR @BrownUPathoGP Why I teach my students about scientific failure https://t.co/BlEq61Za9I
-
-
Mashup Score: 1
BRD8 is identified as a specific epigenetic vulnerability for glioblastomas that harbour wild-type p53.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Dr. Shengliang Zhang @shengliang15 presents an important paper recently published in @Nature about novel epigenetic regulation of p53 in GBM at #eldeirylab meeting @BrownMedicine @BrownUniversity https://t.co/zIbc2Kcy1q https://t.co/x6ttFRIIn8
-
-
Mashup Score: 0
Facility Director, Center for Alzheimer’s Disease Research Fluid Biomarkers Laboratory Biography Kristine Pelton joined the Carney Institute in March of 2022. She has over 15 years of academic research experience focused on preclinical drug development and biomarker-based clinical trials. In her role as Facility Director, Kristine oversees the day-to-day operations of the facility and…
Source: www.brown.eduCategories: Hem/Oncs, Latest HeadlinesTweet-
Thanks to Dr. Kristine Pelton @CarneyInstitute @BrownUniversity for speaking to #eldeirylab @SeanLawler20 @SheldonLHolder @SenduraiMani @biocomicals @LanlanZhou about Fluid Biomarkers core https://t.co/xVJ80QGBDm @BrownUCancer @BrownPathology @BrownMedicine @BrownUResearch https://t.co/ZuXeosOsMc
-
-
Mashup Score: 3Therapeutic targeting of TRAIL death receptors - 1 year(s) ago
The discovery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) along with its potent and selective antitumor effects initiated a decades-long search for therapeutic strategies to target the TRAIL pathway. First-generation approaches were focused on the development of TRAIL receptor agonists (TRAs), including recombinant human TRAIL (rhTRAIL) and TRAIL receptor-targeted agonistic…
Source: Portland PressCategories: Hem/Oncs, Latest HeadlinesTweet-
Happy birthday to @BrownUniversity undergraduate and #eldeirylab member Francesca Di Cristofano @frandicris @BrownUCancer @BrownMedicine and congrats on https://t.co/jUe3hRzryl and upcoming accepted manuscript on novel therapy combo of ABT263 plus ONC201 against solid tumor cells https://t.co/zEHyOqInCA
-
-
Mashup Score: 0Log in or sign up to view - 1 year(s) ago
See posts, photos and more on Facebook.
Source: m.facebook.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Group photo of those who remained till the end of our research lab holiday event at the Hope Club. #eldeirylab @BrownUCancer @BrownMedicine And a few more pictures. https://t.co/1r0HOjszCn
-
-
Mashup Score: 0
TP53 is a tumor suppressor gene that encodes a sequence-specific DNA-binding transcription factor activated by stressful stimuli; it upregulates target genes involved in growth suppression, cell death, DNA repair, metabolism, among others. TP53 is the most frequently mutated gene in tumors, with mutations not only leading to loss-of-function (LOF), but also gain-of-function (GOF) that promotes…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet-
Our most recent #eldeirylab review for therapeutic targeting of the p53 pathway @BrownUCancer @BrownMedicine @BrownUniversity @BrownPathology Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer https://t.co/WdQ6vGzY85
-
New preclinical #eldeirylab results Synergistic activity of ABT-263 and ONC201/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis https://t.co/zDEeFyrBHr